Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Jan 22.
Published in final edited form as: J Org Chem. 2016 Mar 24;81(7):2827–2836. doi: 10.1021/acs.joc.6b00105

Diastereoselective Synthesis of 6″-(Z)- and 6″-(E)-Fluoro Analogues of Anti-hepatitis B Virus Agent Entecavir and Its Evaluation of the Activity and Toxicity Profile of the Diastereomers

Hiroki Kumamoto †,*, Misato Fukano , Tomohiko Nakano , Keito Iwagami , Chiaki Takeyama , Satoru Kohgo §, Shuhei Imoto , Masayuki Amano , Nobuyo Kuwata-Higashi , Manabu Aoki #, Hiroshi Abe , Hiroaki Mitsuya , Kiyoshi Fukuhara , Kazuhiro Haraguchi
PMCID: PMC7821961  NIHMSID: NIHMS1655303  PMID: 27009432

Abstract

A method for the diastereoselective synthesis of 6″-(Z)- and 6″-(E)-fluorinated analogues of the anti-HBV agent entecavir has been developed. Construction of the methylenecyclopentane skeleton of the target molecules has been accomplished by radical-mediated 5-exo-dig cyclization of the selenides 6 and 15 having the phenylsulfanylethynyl structure as a radical accepting moiety. In the radical reaction of the TBS-protected precursor 6, (Z)-anti-12 was formed as a major product. On the other hand, TIPS-protected 15 gave (E)-anti-12. The sulfur-extrusive stannylation of anti-12 furnished a mixture of geometric isomers of the respective vinylstannane, whereas benzoyl-protected 17 underwent the stannylation in the manner of retention of configuration. Following XeF2-mediated fluorination, introduction of the purine base and deoxygenation of the resulting carbocyclic guanosine gave the target (E)- and (Z)-3 after deprotection. Evaluation of the anti-HBV activity of 3 revealed that fluorine-substitution at the 6″-position of entecavir gave rise to a reduction in the cytotoxicity in HepG2 cells with retention of the antiviral activity.

Graphical Abstract

graphic file with name nihms-1655303-f0001.jpg

INTRODUCTION

Hepatitis B is one of the most imperious viral diseases in the world. It has been known to be a major cause of chronic disease, which in turn leads to cirrhosis/hepatocellular carcinoma.1 As one of the best choices for the treatment of this disease,2 entecavir (Baraclude, 1, Figure 1)3a,b has been used for chronic patients due to its lack of significant adverse effects.4 Entecavir is a structurally carbocyclic analogue of deoxyguanosine (dG) and inhibits HBV reverse transcriptase, which in turn leads to chain termination of the positive strand of HBV DNA. The exomethylene functionality at the 6′-position of 1 is an essential pharmacophore for the significant antiviral activity. In fact, the potency of carbocyclic dG 2, which is an analogue lacking the exomethylene functionality, is 10 times less than that of 1.3a To combat the emergence of resistant virus, the development of a more potent and less toxic novel anti-HBV agent is critical. To study the structure–activity relationship of 1, we have designed the 6″-fluorinated analogues 3, which feature polarized exomethylene moieties without alteration of the molecular shape of 1, due to fluorine’s high electronegativity and small van der Waals radius.5a,b Herein, we wish to report the diastereoselective synthesis of (Z)- and (E)-3 based on the 5-exo-dig mode cyclization reaction of 5-hexynyl carbon-radicals having the phenylsulfanylethynyl moiety as a radical accepting group, and the following sulfur-extrusive stannylation of the resulting vinyl sulfide as key steps. Evaluation of their anti-HBV activity and toxicity profiles is also described.

Figure 1.

Figure 1.

Structures of entecavir (1), carbocyclic dG (2), and target molecules (3).

RESULTS AND DISCUSSION

Retrosynthetic analysis for 3 is depicted in Scheme 1. The target molecule 3 would be synthesized by deoxygenation of the 2′-hydroxyl group and subsequent deprotection of the carbocyclic guanosine derivative A. The key intermediate A could be constructed from phenylsulfanyl derivative C by radical-mediated sulfur-extrusive stannylation6 and subsequent electrophilic fluorination of the resulting vinyl stannane B. We have envisioned that the intermediate C can be synthesized by 5-exo-dig mode radical cyclization of a hexynyl radical, utilizing a phenylsulfanylethynyl radical accepting moiety D.

Scheme 1.

Scheme 1.

Retrosynthetic Analysis for 3

Carbon-centered radical-mediated intramolecular cyclization has been demonstrated to be a powerful method for constructing the cyclopentane structure of carbocyclic nucleosides. As shown in Scheme 2, when thiocarbamates 4a7a and 4b7b were reacted with tributyltin hydride/AIBN in benzene under reflux conditions, 5-exo-dig cyclization proceeded to give methylenecyclopentanes 5a and 5b. In this reaction, anti- and syn-isomers were formed in ratios of 3.0:1 to 6.4:1. One would anticipate that, when the radical cyclization reaction is carried out under milder conditions, the chemical yields and diastereoselectivity of anti- and syn-isomers can be improved. Therefore, we have selected the selenide 6 as a radical precursor for D, which enables us to perform the radical reaction at room temperature due to the lower bond energy of the C–Se bond. The synthetic scheme for 6 is illustrated in Scheme 3.

Scheme 2.

Scheme 2.

Precedent Radical-Mediated 5-exo-dig Cyclization Using Thiocarbamates as Precursors

Scheme 3.

Scheme 3.

Preparation of Radical Precursor 6

The starting material was acetylene derivative 7 that was prepared from D-ribose by a literature procedure.8 Compound 7 was reacted with Ph3P=CHOMe to give the enol ether 8 (97% yield), and then the resulting propargyl alcohol was protected with the TBS group to provide 9 (96% yield). Electrophilic phenylselenenylation of the enol ether of 9 by reacting with PhSeCl, followed by DIBAL-H reduction of the resulting aldehyde, gave phenylseleno alcohol 10 as a mixture of diastereomers (ca. 10:1) in moderate yield. Tritylation of the primary alcohol of 10 and subsequent introduction of a phenylthio group at the terminal acetylene of 11 furnished the desired radical precursor 6 in excellent yield.

With the carbon-radical precursor 6 in hand, carbon-centered radical-mediated cyclization of 6 was examined (Scheme 4 and Table 1). When the selenide 6 was treated with tris(trimethylsilyl)silane (TTMSS)9a,b in the presence of AIBN in refluxing toluene, the four isomeric cyclized products (Z)-anti-12, (E)-anti-12, (Z)-syn-13, and (E)-syn-13 were obtained after the removal of the TBS group by treating the reaction mixture with Bu4NF in the presence of AcOH (entry 1). The stereochemistry of the four isomers was determined on the basis of NOE experiments as depicted in Figure 2. The major isomer anti-12 could be isolated in 47% yield (Z/E = 3.8/1) along with the minor syn-isomer (14%, Z/E = 1.4/1). This radical reaction is thought to proceed via a chair form-like transition state I and II (5-exo-dig manner) with the resulting α-phenylsulfanylvinyl radical IIIVI abstracting a hydrogen atom from TTMSS to give 12 and 13. Transition state II is energetically unfavorable due to steric repulsion between the trityloxymethyl and isopropylidene groups. Therefore, the major reaction pathway appears to follow 6I12, leading to the predominant formation of anti-isomer (anti-12/syn-13 = 3.36/1). This is a similar result to that observed in the formation of 5b from 4b.7b Moreover, the predominant formation of the (Z)-isomers most likely reflects a steric interaction between PhS– and TrOCH2–groups because syn-isomer 13 has a lower diastereomeric ratio (Z/E = 1.4/1) than that of anti-12.

Scheme 4.

Scheme 4.

Radical-Mediated 5-exo-dig Cyclization of the Precursors 6, 14, and 15

Table 1.

Radical-Mediated 5-exo-dig Cyclization of Precursors 6, 14, and 15

entry precursor temp. [°C] time [h]a yield [%] of anti-12 (Z/E)b yield [%] of syn-13 (Z/E)b ratio of 12/13
1 6 110c 20 47 (3.8/1) 14 (1.4/1) 3.36/1
2 6 rt 9 63 (11.1/1) 17 (2.9/1) 3.71/1
3 6 −30 20 70 (25.0/1) 17 (5.6/1) 4.12/1
4 6 −70 20d 56 (20.0/1) 3 (1/0) 17.5/1
5 6 −70 96 73 (50.0/1) 14 (9.1/1) 5.21/1
6 14 −70 96 62 (1.0/1) 31 (1.4/1) 2.00/1
7 15 −50 120 69 (1/7.1) 13 (0/1) 5.31/1
a

The reaction times were determined by complete comsumption of the corresponding precursors monitoring by TLC.

b

The ratio of Z/E isomer was determined by integration from 1H NMR spectra.

c

A catalytic amount of AIBN was used as an initiator instead of Et3B.

d

Uncyclized 14 was recovered in 26% after desilylation.

Figure 2.

Figure 2.

NOE Experiments of Compounds 12 and 13.

When the reaction of 6 was carried out at ambient temperature using Et3B as a radical initiator, diastereoselectivities of anti-12/syn-13 and (Z)-/(E)-isomer were slightly improved (entry 2). As can be seen in entries 3 and 4, decreasing the reaction temperature further improved the diastereoselectivity of both the anti-/syn-isomers and (Z)/(E)-isomers. The best result was obtained at −70 °C, in which trans-12 could be obtained in 73% isolated yield (Z/E = 50/1) along with cis-13 (14%, Z/E = 9.1/1) (entry 5). As can be seen in the reaction of 14, the protection of the secondary alcohol at the 1-position was essential for good diastereoselectivity (entry 6).

Interestingly, the (E)-anti-12 was found to be formed as a major product from triisopropylsilyl (TIPS) group-protected 15 under reaction conditions as illustrated in entry 7. In this reaction, the incipient α-phenylsulfanylvinyl radical VII is thought to undergo a 1,6-transfer reaction of a hydrogen atom from the isopropyl group on the silyl protector to the vinyl radical to give a seemingly stable tertiary α-silylalkyl radical VIII, which gave rise to (E)-anti-12 (Scheme 5).10 To validate this assumption, the energy levels of both intermediates VII and VIII were calculated using UB3LYP/6–31G(d,p). As anticipated, the energy level of intermediate VIII is 15.66 kcal/mol lower than that of the vinyl radical VII (see the Supporting Information). However, the possibility of the similar 1,6-hydrogen transfer from the TBS group included in 6 also cannot be ruled out; the actual factor for this opposite stereoselectivity is not clear.

Scheme 5.

Scheme 5.

1,6-Transfer of Hydrogen Atom To Lead to the Predominant Formation of (E)-anti-12

Radical-mediated sulfur-extrusive stannylation was examined next (Scheme 6 and Table 2). When (Z)-anti-12 was treated with Bu3SnH and AIBN in the presence of i-Pr2NEt in refluxing benzene,6f the expected vinyl stannane (Z)-16 was obtained in 75% yield along with its isomer (E)-16 (10%) (entry 1).6e,g The stereochemistry was assigned on the basis of NOE experiments as described in Figure 3. In the case of the benzoate (Z)-17, desired (Z)-18 could be obtained as a sole isomer in 78% yield (entry 2). The isomerization in the sulfur-extrusive stannylation was also observed in the case of (E)-anti-12 to give a mixture of (E)-16 (51%) and (Z)-16 (23%). The remarkable formation of isomerized (Z)-16 could be due to the steric repulsion between the Bu3Sn- and TrOCH2-moieties. To see if this assumption is true, benzoyl group protected (E)-17 was subjected to the radical stannylation, and expectedly, (E)-18 could be obtained in 71% isolated yield as a sole product (entry 4). As shown in entry 5, TMS-protected (E)-19 gave (E)-16 in 72% yield along with the unreacted (E)-12 (22% yield) after desilylation by treatment with NH3/MeOH.

Scheme 6.

Scheme 6.

Sulfur-Extrusive Stannylation of Sulfides 12, 17, and 19

Table 2.

Sulfur-Extrusive Stannylation of the Sulfides 12 and 17

entry precursor yield [%] of stannanes E/Z ratio
1 (Z)-12 75 [(Z)-16], 10 [(E)-16] 1/7.5
2 (Z)-17 78 [(Z)-18] only Z
3 (E)-12 51 [(E)-16], 23 [(Z)-16] 2.22/1
4 (E)-17 71 [(E)-18] only E
5 (E)-19 72 [(E)-16]a,b only E
a

The stannane (E)-16 was obtained after desilylation of intermediate by NH3/MeOH.

b

(E)-12 was recovered in 22% as the unchanged sulfide.

Figure 3.

Figure 3.

NOE Experiments of compounds 12 and 13.

Next, the transformation of 16 and 18 to fluorinated carbocyclic ribonucleosides (Z)- and (E)-23 was examined (Scheme 7). Thus, (E)-16 was reacted with Boc-protected 2-amino-6-chloropurine (20)11a,b under Mitsunobu conditions12 [bis(2-methoxyethyl)azodicarboxylate (DMEAD),13 Ph3P] in toluene under reflux conditions to give 21 in moderate yield. When the vinylstanne 21 was reacted with XeF2, AgOTf, and 2,6-di-tert-butyl-4-methylpyridine (22)14a,b in CH2Cl2, the target 6″-(E)-fluoronucleoside (E)-23 could be obtained in 78% yield. Mitsunobu reaction of (Z)-16, on the other hand, was found to be sluggish even in refluxing xylene, which may be due to the steric repulsion exerted by the bulky Bu3Sn group. This result prompted us to carry out the fluorination of the benzoylated (Z)-18 initially to give the fluoride 24 in 83% yield. Next, Mitsunobu-type substitution reaction between 24 and 20 readily proceeded at room temperature to provide (Z)-23 in good yield.

Scheme 7.

Scheme 7.

Conversion to (Z)- and (E)-23

Finally, deoxygenation of the 2′-position of 23 was examined (Scheme 8). Global deprotection of (E)- and (Z)-23 was carried out by treatment with aqueous TFA or HCO2H to yield the corresponding triols. Silylation of both the 3′- and 5′-hydroxyl groups of the resulting triols using 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane gave (E)- and (Z)-25, respectively. Compound 25 was transformed into the corresponding 2′-O-thiocarbonate and subsequent radical deoxygenation of the thiocarbonate using TTMSS and AIBN provided (E)- and (Z)-26 in moderate yields, respectively. Target (E)- and (Z)-3 were obtained after desilylation of 26 with aqueous TFA. These unsatisfied yields of 3 might be derived from the isolation step by HPLC (the conditions were not optimized), albeit the complete consumption of both of 26 were observed on TLC.

Scheme 8.

Scheme 8.

Transformation to (Z)- and (E)-3

Evaluation of the anti-HBV activity of these synthetic compounds was conducted with HepG2 2.2.15 cells transfected with the HBV genome. As shown in Table 3, (E)-3 possessed a better SI value (116 × 103) than that (28 × 103) of entecavir (1), but significant toxicity to the host cells was observed. In the case of (Z)-3, the potency of its anti-HBV activity is also similar to that of 1. However, it was found that (Z)-3 does not show cytotoxicity against HepG2 cells up to 100 μM and exhibited a better SI value (>23 × 103) than that (21 × 103) of 1 (Table 4). These results indicated that 6″-fluorinated derivatives of entecavir are less toxic analogues with retention of its potent anti-HBV activity. Further studies on the structure–activity relationships of 6″-substituted derivatives of entecavir are underway.

Table 3.

Anti-HBV Activity and Cytotoxicity of (E)-3 and Entecavir (1)

compd. EC50 (μM) CC50 (μM) (HepG2) SI
 (E)-3 0.0003 ± 0.00001 34.9 ± 1.2 116 × 103
1 0.0005 ± 0.0003 13.8 ± 8.3 28 × 103

Table 4.

Anti-HBV Activity and Cytotoxicity of (Z)-3 and Entecavir (1)

compd. EC50 (μM) CC50 (μM) (HepG2) SI
 (Z)-3 0.0044 ± 0.0003 >100 >23 × 103
1 0.0025 ± 0.0002 52.9 21 × 103

EXPERIMENTAL SECTION

General.

NMR (1H, 13C, and 19F) spectra were recorded with 1H, 400 or 500 MHz, 13C, 125 MHz, and 19F, 470 MHz, respectively. Chemical shifts were reported relative to Me4Si, except for fluorine-containing compounds where CFCl3 was used as an internal standard. Mass spectra (MS) were taken in FAB mode with m-nitrobenzyl alcohol as a matrix. HRMS were obtained by the FAB technique with a double sector mass spectrometer. Column chromatography was carried out on silica gel. Thin-layer chromatography (TLC) was performed on a precoated silica gel plate F254. THF was distilled from benzophenone ketyl.

(S)-1-((4S,5R)-5-(2-Methoxyvinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)prop-2-yn-1-ol (8).

To a stirred suspension of Ph3PCH2OCH3Cl (19.9 g, 58.1 mmol) in anhydrous THF (90 mL) was dropwise added t-BuOK (1.0 mol/L in THF, 43.5 mL, 43.5 mmol) at −30 °C. The resulting orange mixture was stirred at rt for 2 h. To the mixture was added a THF (25 mL) solution of 7 (2.67 g, 14.5 mmol) at −30 °C. The mixture was stirred for a further 2.5 h at rt. The resulting mixture was partitioned between Et2O and H2O. Column chromatography on neutral silica gel (hexane/Et2O = 1/1) of the organic layer gave 8 (2.98 g, 97%, E/Z = ca. 3:1) as an oil: [α]D1884.5 (c = 1.30, CHCl3); 1H NMR (400 MHz, C6D6) δ 1.28 (s, 1H), 1.29 (s, 3H), 1.56 (s, 1H), 1.59 (s, 1H), 2.20 (d, J = 2.0 Hz, 1H), 2.21 (d, J = 2.0 Hz, 0.33H), 2.81 (d, J = 7.2 Hz, 1H), 2.92 (d, J = 7.6 Hz, 0.33H), 2.95 (s, 1H), 3.18 (s, 3H), 4.07 (dd, J = 6.8 and 5.2 Hz, 1H), 4.32 (dd, J = 6.8 and 4.8 Hz, 0.33H), 4.34–4.37 (m, 1H), 4.40–4.43 (m, 0.33H), 4.45 (dd, J = 8.8 and 6.4 Hz, 1H), 4.83 (dd, J = 8.4 and 6.4 Hz, 0.33H), 5.08 (dd, J = 12.4 and 9.2 Hz, 1H), 5.38 (ddd, J = 9.6, 6.8, and 1.2 Hz, 0.33H), 5.55 (dd, J = 6.4 and 1.2 Hz, 0.33H), 4.42 (d, J = 12.4 Hz, 1H). 13C NMR (125 MHz, C6D6) δ 0. 25.3, 25.3, 27.4, 27.5, 55.6, 59.4, 62.8, 63.3, 71.5, 74.5, 74.9, 76.3, 80.7, 80.8, 83.5, 83.6, 98.2, 102.5, 108.6, 108.9, 149.2, 151.9. FAB-MS m/z 211 (M+ – H). HRMS (FAB+): calcd for C11H15O4 211.0970, Found 211.0996 [M+ – H].

tert-Butyl(((S)-1-((4R,5R)-5-(2-methoxyvinyl)-2,2-dimethyl-1,3-dioxolan-4-yl)prop-2-yn-1-yl}oxy)dimethylsilane (9).

To a CH2Cl2 (40 mL) solution of 8 (2.74 g, 12.9 mmol) and imidazole (2.63 38.7 mmol) was added TBSCl (2.53 g, 16.8 mmol) at 0 °C. The resulting mixture was stirred at rt for 24 h. The mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. Column chromatography on neutral silica gel (hexane/AcOEt = 5/1) of the organic layer gave 9 (4.04 g, 96%, E/Z = ca. 3:1) as an oil: [α]D18+23.0 (c = 0.90, CHCl3); 1H NMR (400 MHz, C6D6) δ 0.12 (s, 3H), 0.16 (s, 1H), 0.24 (s, 3H), 0.27 (s, 1H), 0.97 (s, 9H), 0.99 (s, 3H), 1.28 (s, 4H), 1.52 (s, 3H), 1.56 (s, 1H), 2.09 (d, J = 2.4 Hz, 1H), 2.11 (d, J = 2.4 Hz, 0.33H), 3.01 (s, 1H), 3.18 (s, 3H), 4.15 (t, J = 6.4 Hz, 1H), 4.30 (t, J = 6.0 Hz, 0.33H), 4.49 (dd, J = 8.8 and 6.0 Hz, 1H), 4.55 (dd, J = 6.0 and 2.4 Hz, 1H), 4.59 (dd, J = 5.6 and 2.4 Hz, 0.33H), 4.82 (dd, J = 9.2 and 6.4 Hz, 0.33H), 5.05 (dd, J = 12.8 and 8.8 Hz, 1H), 5.46 (ddd, J = 9.2, 6.4, and 0.8 Hz, 0.33H), 5.63 (dd, J = 6.4 and 0.8 Hz, 0.33H), 6.42 (d, J = 12.4 Hz, 1H); 13C NMR (125 MHz, C6D6) δ −4.7, −4.5, −3.9, −3.8, 18.3, 18.4, 25.5, 26.0, 27.9, 28.0, 55.6, 59.3, 63.3, 63.8, 71.4, 74.7, 75.0, 76.8, 80.8, 80.9, 83.6, 83.9, 99.5, 102.9, 108.2, 108.4, 149.5, 151.6; FAB-MS m/z 325 (M+ – H). HRMS (FAB+): calcd for C17H29O4Si 325.1835, Found 325.1855 [M+ – H].

2-((4S,5R)-5-((S)-1-((tert-Butyldimethylsilyl)oxy)prop-2-yn-1-yl)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-(phenylselanyl)ethan-1-ol (10).

To a wet THF (150 mL) solution of 9 (9.73 g, 29.8 mmol) was dropwise added a THF (50 mL) solution of PhSeCl (5.99 g, 31.3 mmol) at −80 °C. After 1 h stirring of the resulting mixture, this was stirred at rt for a further 15 min. The mixture was partitioned between aq. saturated NaHCO3 and AcOEt. The organic layer was dried by Na2SO4; then evaporated all of the volatiles without heating. The residue was dissolved in dry THF (150 mL) and then treated with DIBAL-H (1.02 mol/L in toluene, 58.4 mL, 59.6 mmol) at −80 °C. After 1 h stirring at the same temperature, this was partitioned between 0.5 N HCl and AcOEt. The organic layer was dried by Na2SO4 and filtrated through a Celite pad. After evaporation of the filtrate, the residue was purified by column chromatography on silica gel (hexane/AcOEt = 7/1). This gave 10 (9.25 g, 66%, ca. 10:1 of diastereomixture) as an oil: [α]D15+7.8 (c = 0.55, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.08 (s, 3H), 0.14 (s, 0.3H), 0.17 (s, 0.3H), 0.20 (s, 3H), 0.90 (s, 9H), 0.92 (s, 0.9H), 1.35 (s, 0.3H), 1.39 (s, 3H), 1.57 (s, 3H), 1.59 (s, 0.3H), 2.42–2.45 (m, 1H), 2.48 (d, J = 2.0 Hz, 0.1H), 2.55 (d, J = 2.0 Hz, 1H), 2.82–2.86 (m, 0.1H), 3.64–3.86 (m, 3.3H), 4.24 (dd, J = 8.8 and 6.0 Hz, 1H), 4.33 (dd, J = 6.4 and 3.6 Hz, 0.1H), 4.36 (dd, J = 8.8 and 6.4 Hz, 0.1H), 4.43 (t, J = 6.0 Hz, 1H), 4.90–4.94 (m, 1.1H), 7.24–7.34 (m, 3.3H), 7.57–7.63 (m, 2.2H); 13C NMR (125 MHz, CDCl3) δ −4.6, −4.4, −4.3, −3.7, 18.1, 18.4, 24.8, 25.1, 25.8, 25.9, 26.8, 26.9, 45.9, 46.0, 62.3, 63.0, 63.6, 63.7, 75.2, 75.5, 76.9, 78.8, 79.4, 80.8, 83.1, 108.4, 109.4, 126.2, 127.4, 128.0, 128.4, 129.1, 129.3, 135.0, 135.3; FAB-MS m/z 470 (M+ + H). HRMS (FAB+): calcd for C22H34O4SeSi 470.1392, Found 470.1405 [M+].

tert-Butyl(((1S)-1-((4R,5S)-2,2-dimethyl-5-(1-(phenylselanyl)-2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)prop-2-yn-1-yl)oxy)-dimethylsilane (11).

A mixture of 10 (1.75 g, 3.73 mmol), DMAP (503 mg, 4.10 mmol), i-Pr2NEt (1.95 mL, 11.2 mmol), and TrCl (1.56 g, 5.60 mmol) in 1,2-dichloroethane (37 mL) was heated at 70 °C for 40 h. The resulting mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. Column chromatography on silica gel (hexane/AcOEt = 11/1) of the organic layer gave 11 (2.54 g, 96%, ca. 10:1 of diastereomeric mixture) as a foam: [α]D18+100.4 (c = 0.18, CHCl3); 1H NMR (400 MHz, CDCl3) δ −0.04 (s, 3H), 0.11 (s, 0.3H), 0.13 (s, 0.3H), 0.18 (s, 3H), 0.82 (s, 9H), 0.89 (s, 0.9H), 1.32 (s, 0.3H), 1.39 (s, 3H), 1.43 (s, 0.3H), 1.51 (s, 3H), 2.42 (d, J = 2.0 Hz, 0.1H), 2.55 (d, J = 2.0 Hz, 1H), 3.42 (dd, J = 9.2 and 4.0 Hz, 1H), 3.52 (t, J = 9.2 Hz, 1H), 3.60–3.61 (m, 0.2H), 3.64–3.67 (m, 0.1H), 3.74–3.77 (m, 1H), 4.21 (dd, J = 8.8 and 7.2 Hz, 1H), 4.29 (dd, J = 6.4 and 4.4 Hz, 0.1H), 4.50 (dd, J = 9.2 and 6.4 Hz, 0.1H), 4.76–4.77 (m, 0.1H), 4.90 (dd, J = 6.8 and 1.6 Hz, 1H), 5.24 (dd, J = 9.2 and 1.6 Hz, 1H), 7.12–7.82 (m, 22H); 13C NMR for major isomer 11 (125 MHz, CDCl3) δ −4.6, −3.3, 18.1, 24.3, 25.8, 26.0, 44.6, 61.8, 65.2, 75.1, 75.7, 79.5, 83.6, 86.7, 108.6, 126.9, 127.1, 127.7, 128.7, 128.9, 129.8, 133.4, 143.9; 13C NMR for minor isomer 11 (125 MHz, CDCl3) δ −4.5, −4.2, 18.3, 25.0, 25.9, 26.6, 43.2, 62.9, 63.4, 75.0, 76.5, 80.8, 83.4, 86.6, 108.8, 126.9, 127.6, 128.0, 128.6, 128.9, 129.0, 134.6, 144.4; FAB-MS m/z 712 (M+ + H). HRMS (FAB+): calcd for C41H48O4SeSi 712.2487, Found 712.2453 [M+ + H].

tert-Butyl(((1S)-1-((4R,5S)-2,2-dimethyl-5-(1-(phenylselanyl)-2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)-3-(phenylthio)prop-2-yn-1-yl)oxy)dimethylsilane (6).

To a THF (160 mL) solution of 11 (ca. 10:1, 13.2 g, 18.6 mmol) was dropwise added Li-HMDS (1.3 mol/L in THF, 17.8 mL, 23.2 mmol) at −78 °C; then the mixture was stirred for 15 min at the same temperature. To the resulting solution was dropwise added a THF (40 mL) solution of PhSSO2Ph (6.04 g, 24.1 mmol) via cannula. After 50 min stirring at the same temperature, the mixture was partitioned between aq. saturated NH4Cl and AcOEt. Column chromatography on silica gel of the organic layer gave 6 (hexane/AcOEt = 17/1, 13.76 g, 90%, single isomer) as a foam. This was recrystallized from Et2O/hexane: mp 126–128 °C. [α]D180.6 (c = 1.61, CHCl3); 1H NMR (400 MHz, CDCl3) δ −0.03 (s, 3H), 0.15 (s, 3H), 0.83 (s, 9H), 1.40 (s, 3H), 1.52 (s, 3H), 3.43 (dd, J = 9.6 and 4.2 Hz, 1H), 3.53 (t, J = 9.6 Hz, 1H), 3.79–3.83 (m, 1H), 4.31 (dd, J = 8.8 and 7.2 Hz, 1H), 4.93 (dd, J = 7.2 and 2.0 Hz, 1H), 5.46 (d, J = 8.8 Hz, 1H), 7.12–7.15 (m, 2H), 7.18–7.27 (m, 11H), 7.30–7.34 (m, 2H), 7.35–7.40 (m, 8H), 7.46–7.49 (m, 2H); 13C NMR (125 MHz, CDCl3) δ −4.6, −3.4, 18.1, 24.4, 25.9, 26.1, 44.7, 63.0, 65.3, 73.5, 75.7, 79.7, 86.7, 99.0, 108.5, 126.3, 126.4, 126.9, 127.0, 128.7, 128.9, 129.1, 129.8, 132.6, 133.3, 143.9; FAB-MS m/z 820 (M+). Anal. Calcd for C47H52O4SSeSi: C, 68.84; H, 6.39, Found: C, 68.84; H, 6.40.

Radical-Mediated 5-exo-dig Cyclization (Table 1, entry 4).

To a toluene (7.4 mL) solution of 6 (300 mg, 0.37 mmol) and tris(trimethylsilyl)silane (TTMSS) (228 μL, 0.74 mmol) was added freshly opened Et3B (1.0 mol/L in THF, 740 μL, 0.74 mmol) at −70 °C under a positive pressure of dry Ar (including trace amount of O2). The resulting mixture was stirred for 96 h at the same temperature. During this reaction, further Et3B (740 μL) was added every 24 h. The mixture was partitioned between aq. saturated NaHCO3 and AcOEt. Column chromatography on silica gel (hexane/Et2O = 17/1) of the organic layer gave crude cyclized product (228 mg, foam). The mixture was used for the next reaction without further purification. The residue was dissolved in THF (3.7 mL). Then, this was sequentially treated with AcOH (21 μL, 0.37 mmol) and Bu4NF (1.0 mol/L in THF, 1.85 mL, 1.85 mmol). The resulting mixture was heated at 60 °C for 48 h. After disappearance of the silyl ether on TLC (hexane/AcOEt = 3/1), the mixture was partitioned between aq. saturated NaHCO3 and AcOEt. The organic layer was purified by preparative TLC (hexane/AcOEt = 4/1 including 0.5% of Et3N, twice evolution). This gave 12 (148 mg, 73%, Z/E = 50.0:1, as a foam calculated by integration of 1H NMR) and 13 (28 mg, 14%, Z/E = 9.1:1, as a foam), respectively. Analytical samples were prepared by HPLC separation [hexane/AcOEt = 4/1, (Z)-anti-12 (tR = 12.0 min), (E)-anti-12 (tR = 13.8 min), (Z)-syn-13 (tR = 15.8 min), and (E)-syn-13 (tR = 19.3 min)]. When compound 6 (10.0 g, 12.19 mmol) was performed in the same manner, an analytically pure (Z)-anti-12 (4.88 g, 73% as a foam) was obtained after careful purification by column chromatography on silica gel (hexane/Et2O = 10/1 to 4/1). Physical data for (Z)-anti-12: [α]D18α148.1 (c = 0.35, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.36 (s, 3H), 1.50 (s, 3H), 2.84–2.86 (m, 1H), 2.93 (d, J = 8.0 Hz, 1H), 3.14 (dd, J = 9.2 and 4.8 Hz, 1H), 3.25 (dd, J = 9.2 and 4.4 Hz, 1H), 4.46 (dd, J = 6.0 and 1.2 Hz, 1H), 4.74 (t, J = 6.0 Hz, 1H), 4.93 (ddt, J = 8.0, 6.4, and 2.0 Hz, 1H), 6.39 (t, J = 1.6 Hz, 1H), 7.19–7.30 (m, 12H), 7.35–7.40 (m, 8H); 13C NMR (125 MHz, CDCl3) δ 24.8, 26.5, 49.9, 66.1, 73.0, 79.6, 82.5, 87.2, 111.3, 123.1, 126.5, 127.1, 127.9, 128.6, 129.0, 129.3, 137.0, 142.8, 143.6; FAB-MS m/z 550 (M+). Anal. Calcd for C35H34O4S: C, 76.33; H, 6.22, Found: C, 76.54; H,6.32. Physical data for (E)-anti-12: [α]D18258.5 (c = 0.47, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.34 (s, 3H), 1.41 (s, 3H), 2.48 (d, J = 10.8 Hz, 1H), 3.06–3.08 (m, 1H), 3.13 (dd, J = 8.8 and 4.0 Hz, 1H), 3.31 (dd, J = 8.8 and 4.0 Hz, 1H), 4.52 (d, J = 5.6 Hz, 1H), 4.69 (t, J = 5.6 Hz, 1H), 4.83 (ddt, J = 10.8, 6.0, and 2.0 Hz, 1H), 6.57 (t, J = 1.6 Hz, 1H), 7.19–7.25 (m, 5H), 7.27–7.33 (m, 9H), 7.37–7.39 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 25.0, 26.7, 47.8, 64.3, 74.9, 79.0, 81.8, 87.2, 110.7, 118.8, 126.3, 127.1, 127.9, 128.6, 128.6, 129.0, 136.2, 143.6, 147.2; FAB-MS m/z 550 (M+). Anal. Calcd for C35H34O4S·1/2 H2O: C, 75.09; H, 6.30, Found: C, 75.07; H, 6.12. Physical data for (Z)-syn-13: [α]D1848.2 (c = 0.46, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.33 (s, 6H), 2.66–2.70 (m, 1H), 2.84 (d,, J = 8.4 Hz, 1H), 3.24 (dd, J = 9.2 and 7.2 Hz, 1H), 3.61 (dd, J = 9.2 and 6.0 Hz, 1H), 4.50–4.58 (m, 2H), 4.72 (t, J = 5.2 Hz, 1H), 6.26 (t, J = 2.0 Hz, 1H), 7.18–7.30 (m, 14H), 7.43–7.46 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 24.8, 26.0, 44.6, 61.5, 73.3, 78.0, 79.4, 86.8, 111.1, 120.5, 126.2, 126.9, 127.7, 128.6, 128.9, 129.0, 137.3, 140.6, 143.9; FAB-MS m/z 550 (M+). Anal. Calcd for C35H34O4S·1/4 H2O: C, 75.72; H, 6.26, Found: C, 75.58; H, 6.15. Physical data for (E)-syn-13: [α]D18+4.1 (c = 0.51, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.38 (s, 3H), 1.42 (s, 3H), 2.52 (d, J = 8.4 Hz, 1H), 2.85–2.90 (m, 1H), 3.66 (t, J = 8.8 Hz, 1H), 3.69 (dd, J = 8.8 and 5.4 Hz, 1H), 4.13–4.16 (m, 1H), 4.54 (t, J = 6.0 Hz, 1H), 4.97 (t, J = 6.0 Hz, 1H), 6.37 (t, J = 1.6 Hz, 1H), 7.17–7.30 (m, 14H), 7.51–7.53 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 25.0, 26.0, 44.9, 60.7, 73.6, 77.8, 86.9, 111.6, 120.4, 126.5, 126.8, 127.6, 129.0, 129.1, 136.3, 141.5, 144.2; FAB-MS m/z 550 (M+). Anal. Calcd for C35H34O4S: C, 76.33; H, 6.22, Found: C, 76.34; H, 6.28.

(1S)-1-((4S,5S)-2,2-Dimethyl-5-(1-(phenylselanyl)-2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)-3-(phenylthio)prop-2-yn-1-ol (14).

To a mixture of 6 (3.17 g, 3.87 mmol) and AcOH (0.22 mL, 3.87 mmol) in THF (30 mL) was added Bu4NF (1.0 mol/L in THF, 8.5 mL, 8.50 mmol) at 0 °C. The mixture was stirred at rt for 7 h. After evaporation of all of volatiles of the resulting mixture, the residue was purified by column chromatography on silica gel (hexane/AcOEt = 5/1). This gave 14 (2.44 g, 89%) as a foam: [α]D1815.3 (c = 0.35, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.37 (s, 3H), 1.51 (s, 3H), 2.54 (d, J = 7.6 Hz, 1H), 3.41 (d, J = 10.0 and 4.4 Hz, 1H), 3.48 (t, J = 10.0 Hz, 1H), 3.93–3.98 (m, 1H), 4.18 (t, J = 2.8 Hz, 1H), 4.64 (t, J = 2.0 Hz, 1H), 5.05 (t, J = 2.8 Hz, 1H), 7.11–7.15 (m, 2H), 7.18–7.27 (m, 11H), 7.29–7.36 (m, 8H), 7.41–7.47 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 24.9, 26.7, 42.9, 62.8, 65.6, 73.4, 76.6, 79.4, 87.2, 97.7, 108.6, 126.4, 126.6, 127.0, 127.4, 127.8, 128.6, 129.0, 129.2, 132.2, 134.1, 143.7; FAB-MS m/z 707 (M+ + H). Anal. Calcd for C41H38O4SSe·H2O: C, 68.04; H, 5.57, Found: C, 67.84; H, 5.24.

(((1S)-1-((4R,5S)-2,2-Dimethyl-5-(1-(phenylselanyl)-2-(trityloxy)ethyl)-1,3-dioxolan-4-yl)-3-(phenylthio)prop-2-yn-1-yl)oxy)triisopropylsilane (15).

To a mixture of 14 (2.44 g, 3.46 mmol) and 2,6-lutidine (1.53 mL, 13.84 mmol) in CH2Cl2 (35 mL) was dropwise added TIPSOTf (1.9 mL, 6.92 mmol) at 0 °C. The resulting mixture was stirred at rt for 13.5 h. After addition of 0.3 mL of MeOH, the mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. Column chromatography on silica gel (hexane/Et2O = 20/1) of the organic layer gave 15 (2.98 g, 97%) as an oil: [α]D186.1 (c = 0.80, CHCl3); 1H NMR (500 MHz, CDCl3) δ 0.95–1.01 (m, 18H), 1.04–1.11 (m, 3H), 1.42 (s, 3H), 1.52 (s, 3H), 3.44 (dd, J = 10.0 and 4.0 Hz, 1H), 3.55 (t, J = 10.0 Hz, 1H), 3.88–3.91 (m, 1H), 4.33 (dd, J = 9.0 and, 7.5 Hz, 1H), 4.97 (dd, J = 7.5 and 2.5 Hz, 1H), 5.42 (d, J = 9.0 Hz, 1H), 7.00–7.12 (m, 2H), 7.15–7.16 (m, 2H), 7.18–7.27 (m, 9H), 7.29–7.33 (m, 4H), 7.38–7.41 (m, 6H), 7.46–7.47 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 13.0, 18.3, 24.4, 26.1, 44.3, 63.3, 65.2, 73.4, 75.8, 79.8, 86.7, 98.9, 108.4, 126.5, 126.5, 126.8, 126.9, 127.7, 128.6, 128.8, 129.0, 129.9, 132.4, 132.7, 143.9; FAB-MS m/z 901 (M+ + K). Anal. Calcd for C50H58O4SSeSi: C, 69.66; H, 6.78, Found: C, 69.46; H, 6.76.

Sulfur-Extrusive Stannylation of (Z)-anti-12.

A mixture of (Z)-anti-12 (1.24 g, 2.25 mmol), Bu3SnH (1.82 mL, 6.75 mmol), AIBN (186 mg, 1.13 mmol), and i-Pr2NEt (589 μL, 3.38 mmol) in benzene (22.5 mL) was refluxed for 6 h. After evaporation of all of volatiles, the resulting residue was purified by column chromatography on neutral silica gel. This gave (Z)-16 (hexane/Et2O = 15/1, 1.24 g, 75% as an oil) and (E)-16 (hexane/Et2O = 5/1, 172 mg, 10% as an oil), respectively. Physical data for (Z)-16: [α]D205.9 (c = 0.71, CHCl3); 1H NMR (500 MHz, CDCl3) δ 0.85–0.89 (m, 9H), 0.91–0.98 (m, 6H), 1.27–1.35 (m, 6H), 1.32 (s, 3H), 1.48–1.54 (m, 6H), 1.56 (s, 3H), 2.33–2.37 (m, 1H), 2.66–2.67 (m, 1H), 3.08 (dd, J = 8.5 and 4.5 Hz, 1H), 3.21 (dd, J = 8.5 and 4.5 Hz, 1H), 4.40 (d, J = 5.0 Hz, 1H), 4.64–4.68 (m, 2H), 5.98–6.11 (m, 1H), 7.21–7.25 (m, 3H), 7.27–7.30 (m, 6H), 7.37–7.39 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 11.4, 13.7, 24.9, 26.5, 27.4, 29.4, 52.9, 66.2, 74.2, 79.3, 81.0, 87.0, 110.4, 125.9, 127.0, 127.8, 128.6, 143.8, 160.1; FAB-MS m/z 732 (M+ + H). Anal. Calcd for C41H56O4Sn: C, 67.31; H, 7.72, Found: C, 67.33; H, 7.72. Physical data for (E)-16: [α]D16111.8(c = 0.35, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.77–0.90 (m, 15H), 1.19–1.28 (m, 6H), 1.32 (s, 3H), 1.36 (s, 1H), 1.38–1.46 (m, 6H), 2.21–2.25 (m, 1H), 2.50–2.52 (m, 1H), 3.07 (dd, J = 8.8 and 5.6 Hz, 1H), 3.17 (dd, J = 8.8 and 4.0 Hz, 1H), 4.50–4.52 (m, 1H), 4.60–4.66 (m, 2H), 6.13–6.28 (m, 1H), 7.20–7.25 (m, 3H), 7.29–7.30 (m, 6H), 7.35–7.38 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 10.1, 13.6, 24.7, 26.4, 27.3, 29.0, 51.2, 60.0, 74.9, 78.9, 80.4, 87.2, 110.1, 122.3, 127.1, 127.8, 128.7, 143.6, 161.2; FAB-MS m/z 732 (M+ + H). Anal. Calcd for C41H56O4Sn: C, 67.31; H, 7.72, Found: C, 67.40; H, 7.71.

(3aR,4S,6R,6aR,Z)-2,2-Dimethyl-5-((phenylthio)methylene)-6-((trityloxy)methyl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl benzoate (Z)-17.

To a mixture of (Z)-anti-12 (4.86 g, 8.83 mmol), DMAP (1.30 g, 10.6 mmol), and i-Pr2NEt (3.08 mL, 17.7 mmol) in CH2Cl2 (60 mL) was added BzCl (1.55 mL, 13.3 mmol) at 0 °C. The resulting mixture was stirred at rt for 18 h. This was partitioned between aq. saturated NaHCO3 and CH2Cl2. Column chromatography on silica gel (hexane/AcOEt = 5/1) of the organic layer gave (Z)-17 (5.77 g, quant.) as a foam: [α]D19312.6 (c = 0.67, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.27 (s, 3H), 1.29 (s, 3H), 3.07–3.09 (m, 1H), 3.20 (dd, J = 9.2 and 4.8 Hz, 1H), 3.34 (dd, J = 9.2 and 4.0 Hz, 1H), 4.48 (d, J = 5.6 Hz, 1H), 5.04 (t, J = 5.6 Hz, 1H), 5.63–5.95 (m, 1H), 6.53 (t, J = 1.6 Hz, 1H), 7.21–7.32 (m, 14H), 7.41–7.47 (m, 8H), 7.54–7.58 (m, 1H), 8.19–8.21 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 25.5, 26.3, 48.9, 65.8, 74.2, 79.3, 83.4, 87.3, 111.5, 125.0, 126.7, 127.2, 128.0, 128.3, 128.6, 129.0, 129.5, 130.0, 130.1, 132.8, 136.2, 139.5, 143.6, 165.7; FAB-MS m/z 693 (M+ + K). Anal. Calcd for C42H38O5S·1/2 H2O: C, 75.99; H, 5.92, Found: C, 76.08; H, 5.76.

Sulfur-Extrusive Stannylation of (Z)-17.

(Z)-17 (9170 mg, 1.4 mmol) was treated in the same manner as that described for (Z)-anti-12. Column chromatography on silica gel (hexane/AcOEt = 11/1) gave (Z)-18 (910 mg, 78%) as an oil: [α]D19109.1 (c = 0.52, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.74–0.93 (m, 15H), 1.15–1.24 (m, 6H), 1.26 (s, 3H), 1.31 (s, 3H), 1.35–1.44 (m,6H), 2.98–3.00 (m, 1H), 3.22 (dd, J = 8.8 and 4.4 Hz, 1H), 3.35 (dd, J = 8.8 and 4.8 Hz, 1H), 4.44 (dd, J = 6.0 and 1.2 Hz, 1H), 4.94 (t, J = 6.0 Hz, 1H), 5.70–5.73 (m, 1H), 6.11–6.24 (m, 1H), 7.22–7.26 (m, 4H), 7.29–7.33 (m, 5H), 7.42–7.45 (m, 8H), 7.54–7.58 (m, 1H), 8.09–8.11 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 10.2, 13.6, 25.3, 26.5, 27.2, 29.1, 51.7, 65.8, 76.4, 79.0, 82.7, 87.0, 111.3, 127.0, 127.8, 128.2, 128.7, 128.8, 219.9, 130.4, 132.8, 143.8, 157.0, 166.4; FAB-MS m/z 836 (M+ + H). Anal. Calcd for C48H60O5Sn: C, 68.99; H, 7.24, Found: C, 68.96; H, 7.25.

Sulfur-Extrusive Stannylation of (E)-anti-12.

Compound (E)-anti-12 (201 mg, 0.365 mmol) was treated in the same manner as that described for (Z)-anti-12. Column chromatography on silica gel (hexane/Et2O = 15/1 to 5/1) gave (Z)-16 (62 mg, 23%) and (E)-16 (136 mg, 51%), respectively.

(3aR,4S,6R,6aR,E)-2,2-Dimethyl-5-((phenylthio)methylene)-6-((trityloxy)methyl)tetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl Benzoate (E)-17.

(E)-anti-12 (800 mg, 1.45 mmol) was treated in the same manner as that described for (Z)-17. Column chromatography on silica gel (hexane/AcOEt = 7/1) gave (E)-17 (892 mg, 84%) as a foam: [α]D18258.1 (c = 0.51, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.29 (s, 3H), 1.38 (s, 3H), 3.19 (dd, J = 9.2 and 4.0 Hz, 1H), 3.24–3.26 (m, 1H), 3.41 (dd, J = 9.2 and 4.4 Hz, 1H), 4.55 (d, J = 5.2 Hz, 1H), 5.04 (t, J = 1.6 Hz, 1H), 5.90–5.91 (m, 1H), 6.56 (s, 1H), 7.22–7.26 (m, 4H), 7.30–7.37 (m, 10H), 7.43–7.47 (m, 8H), 7.55–7.59 (m, 1H), 8.13–8.14 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 0. 25.5, 26.8, 47.4, 64.0, 76.1, 78.3, 82.6, 87.3, 111.2, 119.5, 126.4, 127.1, 127.9, 128.4, 128.6, 129.1, 129.8, 129.9, 133.1, 136.1, 143.0, 143.6, 165.8; FAB-MS m/z 693 (M+ + K). Anal. Calcd for C42H38O5S·H2O: C, 74.98; H, 5.99, Found: C, 74.71; H, 5.66.

Sulfur-Extrusive Stannylation of (E)-17.

A mixture of (E)-17 (373 mg, 0.57 mmol), Bu3SnH (460 μL, 1.71 mmol), AIBN (47 mg, 0.29 mmol), and i-Pr2NEt (149 μL, 0.86 mmol) in benzene (5.7 mL) was refluxed. After 12 h refluxing, AIBN (47 mg, 0.29 mmol) was added. The resulting mixture was refluxed for a further 12 h. Column chromatography on silica gel of the mixture gave (E)-18 (hexane/Et2O = 7/1, 340 mg, 71% as an oil) and unchanged (E)-17 (hexane/Et2O = 5/1, 32 mg, 9%), respectively: [α]D16123.6 (c = 0.67, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.76–0.92 (m, 15H), 1.21–1.31 (m, 6H), 1.30 (s, 3H), 1.35 (s, 3H), 1.39–1.52 (m, 6H), 2.68–2.69 (m, 1H), 3.15 (dd, J = 8.8 and 5.6 Hz, 1H), 3.19 (dd, J = 8.8 and 4.0 Hz, 1H), 4.56 (d, J = 5.6 Hz, 1H), 4.95–4.98 (m, 1H), 5.75–5.76 (m, 1H), 6.11–6.25 (m, 1H), 7.22–7.26 (m, 4H), 7.29–7.32 (m, 5H), 7.42–7.47 (m, 8H), 7.55–7.59 (m, 1H), 8.13–8.16 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 10.2, 13.7, 25.4, 26.7, 27.3, 29.0, 50.9, 65.9, 76.1, 78.3, 81.6, 87.3, 110.7, 123.7, 127.1, 127.9, 128.3, 128.7, 129.8, 130.3, 132.9, 143.6, 156.1, 166.0; FAB-MS m/z 837 (M+ + H). Anal. Calcd for C48H60O5Sn: C, 68.99; H, 7.24, Found: C, 69.19; H, 7.26.

Sulfur-Extrusive Stannylation of (E)-19.

To a mixture of (E)-12 (1.67 g, 3.03 mmol), imidazole (413 mg, 6.06 mmol), and i-Pr2Net 1.58 mL, 9.09 mmol) in CH2Cl2 (30 mL) was added TMSCl (577 μL, 4.55 mmol) at 0 °C. After 20 nim stirring at this temperature, this was stirred for a further 40 min at rt. The resulting mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. The organic layer was evaporated. The crude TMS ether (E)-19 was used for the next reaction without further purification. To a benzene solution of the above residue were added i-Pr2NEt (793 μL, 4.55 mmol), Bu3SnH (2.45 mL, 9.09 mmol), and AIBN (250 mg, 1.52 mmol). The resulting mixture was refluxed for 12 h. To the mixture was added AIBN (250 mg, 1.52 mmol); then the mixture was refluxed for a further 12 h. After evaporation of all of volatiles, NH3/MeOH (saturated at 0 °C, 40 mL) was added, and the mixture was stirred for 40 h at rt. After evaporation of all of volatiles, the residue was purified by column chromatography on neutral silica gel. This gave (E)-16 (hexane/Et2O = 4/1, 1.6 g, 72%, as an oil) and (E)-anti-12 (hexane/Et2O = 1/1, 375 mg, 22% as a foam), respectively.

Mitsunobu Reaction of (E)-16; Formation of Nucleoside 21.

To a mixture of (E)-16 (5.93 g, 8.1 mmol), Boc-protected 2-amino-6-chloripurine 20 (5.99 g, 16.2 mmol), and Ph3P (4.25 g, 16.2 mmol) in toluene (80 mL) was added DMEAD (3.79 g, 16.2 mmol) at 0 °C. The resulting mixture was stirred for 45 min at the same temperature and then stirred for a further 45 min at rt. The resulting yellow solution was heated at 100 °C for 10 min. The mixture was partitioned between AcOEt and brine. Column chromatography on neutral silica gel of the organic layer (hexane/AcOEt = 5/1) gave 21 (5.38 g, 61%) as a foam: [α]D1686.4 (c = 1.33, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.77–0.94 (m, 15H), 1.21–1.28 (m, 6H), 1.30 (s, 3H), 1.34–1.43 (m, 6H), 1.45 (s, 18H), 1.56 (s, 3H), 2.88 (t, J = 9.0 Hz, 1H), 3.11–3.14 (m, 1H), 3.51 (dd, J = 9.0 and 4.4 Hz, 1H), 4.63–4.71 (m, 1H), 5.18–5.19 (m, 1H), 6.06–6.17 (m, 1H), 7.18–7.25 (m, 9H), 7.34–7.36 (m, 6H), 7.74 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 10.3, 13.7, 25.3, 27.2, 27.5, 27.9, 29.0, 51.7, 65.5, 68.2, 82.4, 83.4, 84.9, 87.6, 111.3, 127.3, 127.9, 128.5, 130.3, 135.4, 143.1, 144.6, 150.6, 150.7, 151.8, 153.0, 154.5;; FAB-MS m/z 1084 (M+ + H). HRMS (FAB+): calcd for C56H75ClN5O7Sn 1084.4377, Found 1084.4355 [M+ + H].

Fluorination of 21; Formation of Fluoride (E)-23.

To a CH2Cl2 (100 mL) solution of 21 (5.20 g, 4.8 mmol), 2,6,-di-tert-butyl-4-methylpyridine (DTBMP, 2.96 g, 14.4 mmol), and XeF2 (1.14 g, 6.72 mmo) was added AgOTf (1.73 g, 6.72 mmol) at 0 °C. The resulting mixture was stirred at rt for 15 min. The mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. Column chromatography on neutral silica gel of the organic layer gave (E)-23 (3.02 g, 78%) as a foam: [α]D1644.6 (c = 0.42, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.30 (s, 3H), 1.45 (s, 18H), 1.54 (s, 3H), 3.18 (dd, J = 9.2 and 6.4 Hz, 1H), 3.40 (dd, J = 9.2 and 6.4 Hz, 1H), 3.57–3.60 (m, 1H), 4.53 (d, J = 5.2 Hz, 1H), 4.89–4.90 (m, 1H), 5.40 (s, 1H), 6.75 (d, JH,F = 80.0 Hz, 1H), 7.22–7.25 (m, 3H), 7.28–7.31 (m, 6H), 7.41–7.45 (m, 6H), 8.01 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 25.0, 27.4, 27.8, 29.7, 46.0, 62.3 (d, JC,F = 8.0 Hz), 63.0, 82.6, 83.6, 85.0, 87.7, 111.8, 121.4 (d, JC,F = 10.8 Hz), 127.4, 128.0, 128.5, 128.6, 130.2, 143.2, 144.0, 150.2 (d, JC,F = 266.3 Hz), 150.6, 151.2, 151.9, 152.5; 19F NMR (470 MHz, CDCl3) δ −120.60 (d, JH,F = 73.4 Hz). FAB-MS m/z 812 (M+ + H). HRMS (FAB+): calcd for C44H48-ClFN5O7 812.3226, Found 812.3256 [M+ + H].

Fluorination of (Z)-18; Formation of Fluoride 24.

To a CH2Cl2 (40 mL) suspension of (Z)-18 (1.54 g, 1.84 mmol), DTBMP (1.13 g, 5.52 mmol), and AgOTf (760 mg, 2.94 mmol) was added XeF2 (840 mg, 0.97 mmol) in one portion at 0 °C. The resulting mixture was stirred at rt for 20 min. The mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. The organic layer was filtrated through a Celite pad. The filtrate was evaporated. The resulting residue was treated with NaOMe (990 mg, 18.4 mmol) and MeOH (40 mL). The mixture was stirred at rt for overnight. The mixture was partitioned between aq. saturated NH4Cl and CHCl3. Column chromatography on silica gel (hexane/AcOEt = 5/1) of the organic layer gave 24 (681 mg, 74%) as a foam: [α]D1663.6 (c = 0.33, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.34 (s, 3H), 1.50 (s, 3H), 2.76–2.79 (m, 1H), 2.83 (d, J = 7.2 Hz, 1H), 3.11 (dd, J = 9.2 and 5.2 Hz, 1H), 3.16 (dd, J = 9.2 and 4.8 Hz, 1H), 4.38 (dt, J = 6.0 and 2.0 Hz, 1H), 4.61 (t, J = 6.0 Hz, 1H), 4.90–4.93 (m, 1H), 6.59 (dt, JH,F = 82.8 Hz, J = 2.0 Hz, 1H), 7.22–7.26 (m, 3H), 7.29–7.32 (m, 6H), 7.37–7.40 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 24.8, 26.4, 29.7, 44.5 (d, JC,F = 6.0 Hz), 65.9, 70.8, 77.2, 82.4, 87.2, 111.6, 126.1 (d, JC,F = 2.4 Hz), 127.2, 127.9, 128.6, 143.5, 147.0 (d, JC,F = 261.0 Hz); 19F NMR (470 MHz, CDCl3) δ−132.88 (d, JH,F = 73.8 Hz). FAB-MS m/z 499 (M+ + K). Anal. Calcd for C29H29FO4·4/5 H2O: C, 73.34; H, 6.49, Found: C, 73.02; H,6.28.

Mitsunobu Reaction of 24: Formation of (Z)-23.

To a THF (50 mL) solution of 24 (1.69 g, 3.67 mmol), Boc-protected 2-amino-6-chloripurine 20 (2.71 g, 7.34 mmol), and Ph3P (1.93 g, 7.34 mmol) was added di(methoxyethyl)azodicarboxylate (DMEAD) (1.72 g, 7.34 mmol) at 0 °C. After 2 h stirring of the resulting mixture, this was stirred for a further 18 h at rt. The mixture was partitioned between H2O and AcOEt. Column chromatography on silica gel (hexane/AcOEt = 4/1) of the organic layer gave (Z)-23 (2.35 g, 79%) as a foam: [α]D16+1.4 (c = 0.95, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.30 (s, 3H), 1.44 (s, 18H), 1.53 (s, 3H), 3.10–3.13 (m, 1H), 3.16 (t, J = 8.8 Hz, 1H), 3.42 (dd, J = 8.8 and 4.8 Hz, 1H), 4.63–4.64 (m, 1H), 4.88 (d, J = 2.0 Hz, 1H), 6.76 (d, JH,F = 81.6 Hz, 1H), 7.20–7.29 (m, 9H), 7.37–7.39 (m, 6H), 7.91 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 25.0, 27.3, 27.8, 46.8 (d, JC,F = 2.4 Hz), 60.9, 64.1, 82.2, 83.5, 85.2, 87.6, 111.9, 120.9 (d, JC,F = 4.8 Hz), 127.3, 128.0, 128.4, 130.1, 143.3, 144.7, 149.4 (d, JC,F = 273.5 Hz), 150.4, 150.9, 151.7, 152.0; 19F NMR (470 MHz, CDCl3) δ –119.86 (d, JH,F = 88.8 Hz). FAB-MS m/z 812 (M+), 850 (M+ + K). Anal. Calcd for C44H47ClFN5O7: C, 65.06; H, 5.83; N, 8.62, Found: C, 65.14; H, 5.82; N, 8.62.

Deprotection and Subsequent Silylation of (E)-23; Formation of (E)-25.

To a mixture of (E)-23 (550 mg, 0.68 mmol) in H2O (6 mL) was added TFA (6 nL). The resulting yellow suspension was stirred at rt for 48 h. To the mixture was added EtOH (10 mL), then evaporated all of volatiles. This azeotropic evaporation was repeated three times. The residue was treated with NH3/MeOH (0 °C saturated, 30 mL). The resulting mixture was stirred for 15 min at rt. The mixture was evaporated until most of the MeOH was eliminated. To the residue was added DMF (5 mL), then evaporated under azeotropic conditions using toluene. The resulting solid was dried for 48 h under vacuum condition. To a DMF (13.5 mL) solution of the above residue and imidazole (138 mg, 2.03 mmol) was dropwise added 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPDSCl2, 213 μL, 0.68 mmol) at 0 °C. The resulting mixture was stirred for a further 1 h at the same temperature. To this was added H2O (30 mL), and then it was extracted by AcOEt. After evaporation of all of the volatiles of the organic layer, the residue was purified by column chromatography on silica gel (AcOEt/80%MeOH = 30/1). This gave (E)-25 (220 mg, 59%) as a solid: mp > 250 °C; [α]D1354.8 (c = 0.12, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 0.91–1.06 (m, 1H), 2.96–2.99 (m, 1H), 4.13–4.27 (m, 4H), 4.92 (d, J = 3.6 Hz, 1H), 5.36 (d, J = 5.2 Hz, 1H), 6.47 (br-s, 2H), 6.84 (d, JH,F = 82.8 Hz, 1H), 7.59 (s, 1H), 10.59 (br-s, 1H); 13C NMR (125 MHz, DMSO-d6) δ 12.1, 12.8, 13.0, 13.1, 17.0, 17.0, 17.0, 17.1, 17.4, 17.4, 17.5, 17.7, 47.4, 58.0 (d, JC,F = 9.6 Hz), 60.5, 72.2, 74.3, 116.9, 118.7 (d, JC,F = 7.2 Hz), 135.3, 149.9 (d, JC,F = 259.1 Hz), 151.3, 153.7, 157.0; 19F NMR (470 MHz, DMSO-d6) δ −127.15 (d, JH,F = 74.3 Hz). FAB-MS m/z 554 (M+ + H). HRMS (FAB+): calcd for C24H41FN5O5Si2 554.2630, Found 554.2635 [M+ + H].

Deprotection and Subsequent Silylation of (Z)-23; Formation of (Z)-25.

Compound (Z)-23 (2.29 g, 2.82 mmol) was dissolved in THF (8 mL) and 80% HCO2H (30 mL). The resulting mixture was heated at 60 °C for 4 h. After evaporation of all of the volatiles, the residue was coevaporated with EtOH (ca. 30 mL). This was treated with NH3/MeOH (0 °C saturated, ca. 30 mL). The residue was evaporated, then coevaporated with toluene (ca. 30 mL) for three times. The resulting residue was dissolved in pyridine (50 mL). To the suspension was added TIPDSCl2 (933 μL, 2.96 mmol) at 0 °C. The resulting suspension was stirred for 20 h at the same temperature. The mixture was treated with crushed ice. After 20 min stirring, the mixture was adsorbed with silica gel. Column chromatography on silica gel (AcOEt/MeOH = 50/1 containing 0.25% of H2O) gave (Z)-25 (992 mg, 64%) as a solid. mp > 250 (dec) °C; [α]D14+1.3 (c = 0.67, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 0.88–1.07 (m, 27H), 2.85–2.86 (m, 1H), 3.16 (d, J = 5.2 Hz, 1H), 3.88 (t, J = 3.6 Hz, 1H), 4.18–4.22 (m, 2H), 5.00 (s, 1H), 5.45 (d, J = 4.4 Hz,1 H), 6.51 (br-s, 2H), 7.18 (d, JH,F = 81.6 Hz, 1H), 7.42 (s, 1H), 10.60 (br-s, 1H); 13C NMR (125 MHz, DMSO-d6) δ 12.0, 12.6, 12.6, 12.7, 16.8, 16.9, 16.9, 17.0, 17.2, 17.2, 17.3, 17.5, 43.6, 56.4, 59.3, 71.8, 74.8, 116.5, 118.5 (d, JC,F = 6.0 Hz), 134.3, 149.0 (d, JC,F = 257.9 Hz), 150.9, 153.7, 156.7; 19F NMR (470 MHz, DMSO-d6) δ −127.48 (d, JH,F = 88.8 Hz). FAB-MS m/z 554 (M+ + H). Anal. Calcd for C24H40FN5O5Si2·1/2 H2O: C, 51.22; H, 7.34; N, 12.44, Found: C, 51.09; H, 7.25; N, 12.23.

Radical Deoxygenation of (E)-25; Formation of (E)-26.

To a mixture of (E)-25 (226 mg, 0.41 mmol), DMAP (55 mg, 0.45 mmol), and i-Pr2NEt (178 μL, 1.02 mmol) in CH2Cl2 (8 mL) was added PhOC(S)Cl (141 μL, 1.02 mmol) at 0 °C. The resulting mixture was stirred at the same temperature for 1 h. The mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. The inorganic layer was further washed with AcOEt. The combined organic layer was evaporated. The residue was roughly purified by column chromatography on silica gel (AcOEt/i-PrOH = 7/1). This gave a crude thiocarbonate. This was used for next reaction without further purification. A mixture of the thiocarbonate, TTMSS (315 μL, 1.02 mmol), and AIBN (34 mg, 0.21 mmol) in toluene (8 mL) was heated at 100 °C for 0.5 h. The mixture was purified by column chromatography on silica gel (AcOEt/80%MeOH = 50/1). This gave (E)-26 (148 mg, 67%) as a solid. mp > 240 (dec) °C; [α]D148.0 (c = 0.67, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 0.91–1.05 (m, 28H), 2.10–2.17 (m, 1H), 2.45–2.47 (m, 1H), 2.83–2.87 (m, 1H), 3.99 (dd, J = 11.6 and 7.2 Hz, 1H), 4.16 (dd, J = 11.6 and 4.4 Hz, 1H), 4.50–4.52 (m, 1H), 5.21–5.24 (m, 1H), 6.47 (br-s, 2H), 7.00 (d, JH,F = 83.6 Hz, 1H), 7.57 (s, 1H), 10.60 (br-s, 1H); 13C NMR (125 MHz, DMSO-d6) δ 12.1, 12.6, 13.0, 13.0, 17.0, 17.1, 17.4, 17.4, 17.5, 17.7, 39.9, 51.4, 52.0 (d, JC,F = 10.7 Hz), 61.7 (d, JC,F = 4.7 Hz), 72.7, 117.1, 121.1 (d, JC,F = 7.2 Hz), 135.1, 149.8 (d, JC,F = 258.7 Hz), 151.1, 153.7, 157.0; 19F NMR (470 MHz, DMSO-d6) δ−127.48 (d, JH,F = 88.8 Hz). FAB-MS m/z 538 (M+ + H). HRMS (FAB+): calcd for C24H41-FN5O4Si2 538.2681, Found 538.2701 [M+ + H].

Radical Deoxygenation of (Z)-25; Formation of (Z)-26.

To a mixture of (Z)-25 (177 mg, 0.32 mmol), DMAP (43 mg, 0.35 mmol), and i-Pr2NEt (140 μL, 0.8 mmol) was added PhOC(S)Cl (110 μL, 0.8 mmol) at 0 °C. The resulting solution was stirred at the same temperature for 1 h. The mixture was partitioned between aq. saturated NaHCO3 and CH2Cl2. The inorganic layer was further extracted by AcOEt. After evaporation of all of the volatiles of the combined organic layer, the residue was roughly purified by column chromatography on silica gel (AcOEt/i-PrOH = 7/1). This gave a crude thiocarbonate. This was used for the next step without further purification. The crude thiocarbonate was dissolved in degassed toluene; to this were sequentially added TTMSS (247 μL, 0.8 mmol) and AIBN (26 mg, 0.16 mmol). The resulting mixture was heated at 100 °C for 0.5 h. Column chromatography on silica gel (AcOEt/80% MeOH = 50/1) of the resulting mixture gave (Z)-26 (103 mg, 60%) as a foam: [α]D14+18.1 (c = 0.08, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 0.90–1.05 (m, 28H), 2.00 (dd, J = 12.8 and 6.0 Hz, 1H), 2.12–2.20 (m, 1H), 2.59–2.61 (m, 1H), 4.01 (dd, J = 12.0 and 3.6 Hz, 1H), 4.14 (dd, J = 12.0 and 3.6 Hz, 1H), 4.38–4.44 (m, 1H), 5.35 (d, J = 7.6 Hz, 1H), 6.50 (br-s, 2H), 7.10 (d, JH,F = 81.2 Hz, 1H), 7.43 (s, 1H), 10.61 (br-s, 1H); 13C NMR (125 MHz, DMSO-d6) δ 12.0, 12.4, 12.6, 12.6, 16.9, 16.9, 17.0, 17.2, 17.2, 17.3, 17.4, 39.7, 48.7 (d, JC,F = 2.4 Hz), 49.1 (d, JC,F = 3.6 Hz), 59.7, 71.1, 116.4, 120.1 (d, JC,F = 7.2 Hz), 134.5, 148.0 (d, JC,F = 257.9 Hz), 150.7, 153.6, 156.7; 19F NMR (470 MHz, DMSO-d6) δ −126.91 (d, JH,F = 88.8 Hz). FAB-MS m/z 538 (M+ + H). HRMS (FAB+): calcd for C24H41FN5O4Si2 538.2681, Found 538.2685 [M+ + H].

2-Amino-9-((1S,3R,4S,E)-2-(fluoromethylene)-4-hydroxy-3-(hydroxymethyl)cyclopentyl)-1,9-dihydro-6H-purin-6-one (E)-3.

To a THF (2 mL) solution of (E)-26 (145 mg, 0.27 mmol) was added 80% TFA (5 mL). The mixture was stirred at rt for 24 h. After evaporation of all of the volatiles, the residue was treated with NH3/MeOH (0 °C saturated, 5 mL) at rt for 15 min. The resulting mixture was evaporated. The residue was purified by reverse phase HPLC (7% MeCN in H2O containing 0.1% of AcOH, 20 mL/min, tR = 7.9 min). This gave (E)-3 (17 mg, 21%) as a solid: mp 228–230 °C; [α]D141.6 (c = 0.67, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 2.01–2.06 (m, 1H), 2.24–2.30 (m, 1H), 2.78 (br-s, 1H), 3.55–3.66 (m, 2H), 4.27 (br-s, 1H), 4.92 (d, J = 2.8 Hz, 1H), 4.96 (t, J = 1.6 Hz, 1H), 5.41–5.43 (m, 1H), 6.42 (s, 2H), 6.62 (d, JH,F = 82.8 Hz, 1H), 7.77 (s, 1H), 10.55 (br-s, 1H); 13C NMR (125 MHz, DMSO-d6) δ 40.1, 52.1, 52.2, 60.6, 71.2, 116.6, 124.9 (d, JC,F = 8.4 Hz), 135.9, 148.2 (d, JC,F = 254.3 Hz), 151.3, 153.7, 157.0; 19F NMR (470 MHz, DMSO-d6) δ−131.23 (d, JH,F = 88.8 Hz). FAB-MS m/z 296 (M+ + H). HRMS (FAB+): calcd for C12H15FN5O3 296.1159, Found 296.1161 [M+ + H].

2-Amino-9-((1S,3R,4S,Z)-2-(fluoromethylene)-4-hydroxy-3-(hydroxymethyl)cyclopentyl)-1,9-dihydro-6H-purin-6-one (Z)-3.

Compound (Z)-26 (157 mg, 0.29 mmol) was treated with the same procedure as that described for (E)-26. The mixture was purified by reverse phase HPLC (7% MeCN in H2O containing 0.1% of TFA, 20 mL/min, tR = 3.4–6.2 min). After evaporation of all of the volatiles, the residue was triturated with MeCN. The precipitate was collected and dried in vacuo. This gave (Z)-3 (42 mg, 49%) as a solid: mp > 210 (dec) °C; [α]D16+35.3 (c = 0.11, MeOH); 1H NMR (400 MHz, DMSO-d6) δ 2.04–2.08 (m, 2H), 2.50–2.52 (m, 1H), 3.50–3.56 (m, 1H), 3.63–3.67 (m, 1H), 4.17 (br-s, 1H), 4.96–4.97 (m, 2H), 5.48–5.50 (m, 1H), 6.41 (br-s, 2H), 6.88 (d, JH,F = 83.2 Hz, 1H), 7.67 (s, 1H); 13C NMR (125 MHz, DMSO-d6) δ 40.9, 50.8 (d, JC,F = 3.6 Hz), 51.4, 62.2, 71.0, 116.2, 123.1 (d, JC,F = 3.6 Hz), 135.8, 147.1 (d, JC,F = 257.9 Hz), 150.9, 153.4, 156.8; 19F NMR (470 MHz, DMSO-d6) δ −127.12 (d, JH,F = 87.2 Hz). FAB-MS m/z 296 (M+ + H). HRMS (FAB+): calcd for C12H15FN5O3 296.1159, Found 296.1163 [M+ + H].

Supplementary Material

Supplemental figures

ACKNOWLEDGMENTS

Financial support from the Japan Society for the Promotion of Science (KAKENHI No. 24590144 to K.H.) and a Health and Labor Sciences Research Grant [Practical Research on Hepatitis (Research on the innovative development and the practical application of new drugs for hepatitis B)] is gratefully acknowledged. The authors are also grateful to Miss Y. Odanaka and Mrs.S. Matsubayashi (Center for Instrumental Analysis, Showa University) for technical assistance with NMR, MS, and elemental analyses.

Footnotes

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b00105.

1H and 13C NMR spectra for all new compounds and calculated structures of intermediates VII and VIII (PDF)

The authors declare no competing financial interest.

REFERENCES

  • (1).White DO; Fenner FJ Medical Virology, 4th ed.; Academic: New York, 1994; Chapter 22. [Google Scholar]
  • (2).Dienstag JL N. Engl. J. Med. 2008, 359, 1486–1500. [DOI] [PubMed] [Google Scholar]
  • (3) (a).Innaimo SF; Seifer M; Bisacchi GS; Stabdring DN; Zahler R; Colonno RJ Antimicrob. Agents Chemother. 1997, 41, 1444–1448. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Yamanaka G; Wilson T; Innaimo S; Bisacchi GS; Egli P; Rinehart JK; Zahler R; Colonno RJ Antimicrob. Agents Chemother. 1999, 43, 190–193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (4) (a).Will H; Reiser W; Weimer T; Pfaff E; Büscher M; Sprengel R; Cattaneo R; Schaller HJ Virol. 1987, 61, 904–911. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Scott LJ; Keating GM Drugs 2009, 69, 1003–1033. [DOI] [PubMed] [Google Scholar]
  • (5).(a) As selected reviews, see: Wang J; Sánchez-Roselló M; Aceña L; del Pozo C; Sorochinsky AL; Fustero S; Soloshonok VA; Liu H. Chem. Rev. 2014, 114, 2432–2506. [DOI] [PubMed] [Google Scholar]; (b) Qiu X-L; Xu XH; Qing F-L Tetrahedron 2010, 66, 789–843. [Google Scholar]
  • (6) (a).Watanabe Y; Ueno Y; Araki T; Endo T; Okawara M Tetrahedron Lett. 1986, 27, 215–218. [Google Scholar]; (b) Dubois E; Beau J-M Tetrahedron Lett. 1990, 31, 5165–5168. [Google Scholar]; (c) McCarthy JR; Matthews DP; Stemerick DM; Huber EW; Bey P; Lippert BJ; Snyder RD; Sunkara PS J. Am. Chem. Soc. 1991, 113, 7439–7440. [Google Scholar]; (d) Wnuk SF; Robins MJ Can. J. Chem. 1993, 71, 192–198. [Google Scholar]; (e) McCarthy JR; Huber EW; Le T-B; Laskovics FM; Matthews DP Tetrahedron 1996, 52, 45–58. [Google Scholar]; (f) Onuma S; Kumamoto H; Kawato K; Tanaka H Tetrahedron 2002, 58, 2497–2503. [Google Scholar]; (g) Kumamoto H; Onuma S; Tanaka HJ Org. Chem. 2004, 69, 72–78. [DOI] [PubMed] [Google Scholar]; (h) Kumamoto H; Deguchi K; Wagata T; Furuya Y; Odanaka Y; Kitade Y; Tanaka H Tetrahedron 2009, 65, 8007–8013. [Google Scholar]
  • (7) (a).Gaudino JJ; Wilcox CS J. Am. Chem. Soc. 1990, 112, 4374–4380. [Google Scholar]; (b) Takagi C; Sukeda M; Kim H-S; Wataya Y; Yabe S; Kitade Y; Matsuda A; Shuto S Org. Biomol. Chem. 2005, 3, 1245–1251. [DOI] [PubMed] [Google Scholar]
  • (8).Marco-Contelles J; Destabel C; Gallego P; Chiara JL; Bernabé MJ Org. Chem. 1996, 61, 1354–1362. [Google Scholar]
  • (9) (a).Chatgilialoglu C; Griller D; Lesage MJ Org. Chem. 1988, 53, 3641–3642. [Google Scholar]; (b) As a review, see: Chatgilialoglu C. Chem.—Eur. J. 2008, 14, 2310–2320. [DOI] [PubMed] [Google Scholar]
  • (10).(a) Examples of 1,6 hydrogen transfer on the α-silyl radicals; see: Bogen S; Fensterbank L; Malacria M J. Am. Chem. Soc. 1997, 119, 5037–5038. [Google Scholar]; (b) Bogen S; Fensterbank L; Malacria MJ Org. Chem. 1999, 64, 819–825. [DOI] [PubMed] [Google Scholar]
  • (11) (a).Dey S; Garner PJ Org. Chem. 2000, 65, 7697–7699. [DOI] [PubMed] [Google Scholar]; (b) Fletcher S; Shahani VM; Lough AJ; Gunning PT Tetrahedron 2010, 66, 4621–4632. [Google Scholar]
  • (12).Mitsunobu O Synthesis 1981, 1981, 1–28. [Google Scholar]
  • (13).Sugimura T; Hagiya K Chem. Lett. 2007, 36, 566–567. [Google Scholar]
  • (14) (a).Tius MA; Kawakami JK Synth. Commun. 1992, 22, 1461–1471. [Google Scholar]; (b) As a review, see: Tius MA. Tetrahedron 1995, 51, 6605–6634. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental figures

RESOURCES